Quick Take
Vir Biotechnology (VIR) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing therapeutics for serious immune system and infectious diseases.
VIR is using Alnylam’s siRNA technology platform for its lead candidate and has an option to use the technology for another four candidates.
When I learn more pricing and valuation IPO details, I’ll provide an update.
Company & Technology
San Francisco, California-based Vir was founded in 2016 to develop antibody-based treatment candidates for hepatitis and other